retatrutide ly3437943 parkinson's disease clinical trial The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor Retatrutide Results: 28.3% Weight Loss
Description
Is the science solid and what affects SIRT1?
Cai et al., JAMA Ophthalmol 2025
Repeated blood samples were obtained, and the following endocrine markers were measured: total ghrelin, acyl-ghrelin, leptin, glucagon-like peptide-1 (GLP-1), and insulin
Standards of Care in Diabetes2025
Not intended for individuals under 18, pregnant or nursing individuals, or anyone with a known medical condition or taking medication including GLP-1 medications
GLP-1 agonists are a class of drugs with a growing reputation for their role in weight management
